Trial intelligence / Profile preview

Double-blind randomized phase 3 trial of imiquimod 5% cream vs Aldara 5% cream vs vehicle in actinic keratosis

2016-000712-15Phase 3Completed

Sponsor
Dermapharm
Start
Oct 2016
Modality
Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial of imiquimod in actinic keratosis (AK) (3 arms), sponsored by Dermapharm. Primary endpoint: Clinical success at 4 weeks post treatment. Started Oct 2016; status: completed.

02

Drugs

imiquimod
03

Conditions

actinic keratosis (AK)

Beyond the preview

Go deeper on 2016-000712-15.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2016-000712-15.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call